Boehringer Ingelheim half-year results 2023 Boehringer Ingelheim half-year results 2023 First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Boehringer-Ingelheim's-half-year-figures-2021 Boehringer-Ingelheim's-half-year-figures-2021 Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Strategic-collaboration-with-EnaraBio Strategic-collaboration-with-EnaraBio Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
emperor-preserved-kidney-subanalysis emperor-preserved-kidney-subanalysis New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
biopharmaceuticals-in-china biopharmaceuticals-in-china Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Targeting HER2 in cancer: The story of zongertinib Targeting HER2 in cancer: The story of zongertinib We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
empulse-trial-benefit-acute-heart-failure empulse-trial-benefit-acute-heart-failure Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
emperor-reduced-chmp-positive-opinion emperor-reduced-chmp-positive-opinion CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
DCRI-collaboration-empact-mi DCRI-collaboration-empact-mi Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Oncology and Cancer Immunology Research Oncology and Cancer Immunology Research Find out more about our research and development in oncology and cancer immunology.
Improving lives by providing better access to treatments Improving lives by providing better access to treatments Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
reduced-heart-failure-treatment-approval-europe reduced-heart-failure-treatment-approval-europe European approval for treatment of adults with heart failure with reduced ejection fraction
CARMELINA-elderly-analysis CARMELINA-elderly-analysis CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Breakthrough Designation granted in US and China Breakthrough Designation granted in US and China SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Stroke Risk Factors Symptoms Stroke Risk Factors Symptoms Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
SPEVIGO® SPEVIGO® SPEVIGO® (spesolimab) is a novel, humanized, selective antibody for the treatment of generalized pustular psoriasis (GPP) flares.
Our Partners_ViraTherapeutics Our Partners_ViraTherapeutics Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
emperor-reduced-heart-failure-toplineresults emperor-reduced-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
Anna Race Anna Race Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.